jbainseky, I don't see your scenario as likely. As I understand it, you are suggesting that PPHM has a suitor that has had a history of interest in buying out the company, such that PPHM has taken measures to adjust the poison pill consequence down to about three times trading price, or something like that.
For starters, I would be surprised if many long term longs would be interested in selling their shares at a $2.20 pre split basis if PPHM is delivering on its technology, per plan. New entrants might, but it seems likely that most of shares have been held long since the period when the pps exceeded $2 pre split four years and six years ago.
Put another way, have there been PPHM business plan developments over the last five years that would leave long investors satisfied to accept a buyout price that was available through normal trading before Bavi was announced as safe and well tolerated in human trials? To answer to that question, PPHM investors have seen achievement of government funding for anti-viral research, Avid sales growth and trial results for both Cotara and Bavi that indicate these products are outperforming standard of care. With the addition of experienced staff and contract consultants that have a record of success and final results from ongoing trials due in 2010, it seems that PPHM is well positioned to finally start realizing share holder value as reflected in the pps.
We all saw last week how the PPHM executive team and key employees have been granted incentives through options that can bring multi-million dollar rewards for achieving PPHM performance mile stones and pps appreciation. The schedule laid out over the next year for performance targets that trigger release of stock incentives to management is more than just a hint about the time frame under which investors can expect to see results.
Best wishes and IMO.
KT
News 
Market Data 
Discover 
AI
